

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of claims:**

1. **(Currently Amended)** A method for determining whether ~~an agent selected from the group consisting of TAXOL, TAXOL mimics, TAXOL analogs, TAXOL derivatives, cisplatin, cisplatin mimics, cisplatin analogs~~ paclitaxel and ~~cisplatin derivatives~~ can be used to reduce the growth of an ovarian tumor, comprising the steps of:

- a) obtaining a sample of ovarian tumor cells;
- b) determining whether the ovarian tumor cells express one or more sensitivity markers identified in Tables 1-6; and
- c) identifying that paclitaxel and cisplatin ~~the agent~~ can be used to reduce the growth of the ovarian tumor cells when the one or more sensitivity markers are expressed.

2-4. **(Cancelled)**

5. **(Currently Amended)** The method of claim 70, wherein expression is determined by detecting the amount of an mRNA molecule comprising the corresponding RNA sequence of the polynucleotide sequence of SEQ ID NO:16 mRNA present in the sample.

6. **(Cancelled)**

7. **(Previously Presented)** The method of claim 1, wherein said ovarian tumor cells are obtained from an ovarian tumor cell line or an ovarian tumor obtained from a subject.

8. **(Currently Amended)** A method for determining whether ~~an agent selected from the group consisting of TAXOL, TAXOL mimics, TAXOL analogs, TAXOL derivatives, cisplatin, cisplatin mimics, cisplatin analogs~~ paclitaxel and ~~cisplatin derivatives~~ cannot be used to reduce the growth of an ovarian tumor, comprising the steps of:

- a) obtaining a sample of ovarian tumor cells;

- b) determining whether the ovarian tumor cells express one or more markers selected from the group consisting of the sensitivity markers identified in Tables 1-6; and
- c) identifying that paclitaxel and cisplatin ~~the agent~~ cannot be used to reduce the growth of the ovarian tumor when one or more of the sensitivity markers in Tables 1-6 is not expressed ~~or is underexpressed~~ by the ovarian tumor cells.

9-11. (Cancelled)

12. (Currently Amended) The method of claim 71, wherein expression is determined by detecting the amount of an mRNA molecule comprising the corresponding RNA sequence of the polynucleotide sequence of SEQ ID NO:16 ~~mRNA~~ present in the sample.

13. (Cancelled)

14. (Previously Presented) The method of claim 8, wherein said ovarian tumor cells are obtained from an ovarian tumor cell line or an ovarian tumor obtained from a subject.

15-69. (Cancelled)

70. (Previously Presented) The method of claim 1, wherein the sensitivity marker is the marker of SEQ ID NO:16.

71. (Previously Presented) The method of claim 8, wherein the sensitivity marker is the marker of SEQ ID NO:16.